Filed by Social Capital Suvretta Holdings Corp. I
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Akili Interactive Labs, Inc.
Registration No.: 333-262706
Date: April 12, 2022
This filing relates to
the proposed merger of Akili Interactive Labs, Inc., a Delaware corporation (Target), with Karibu Merger Sub, Inc. (Merger Sub), a Delaware corporation and a wholly owned subsidiary of Social Capital Suvretta Holdings Corp.
I, a Cayman Islands exempted company limited by shares (SPAC), pursuant to the terms of that certain Agreement and Plan of Merger, dated as of January 26, 2022, by and among SPAC, Merger Sub and Target.
The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactives Digital Therapeutic AKL-T03 Improves Cognitive Impairments in
Adults with Major Depressive Disorder When Combined with Antidepressant Medication
AKL-T03 showed a statistically significant improvement in
sustained attention compared to control intervention.
AKL-T03 is built on the same technology engine as Akilis digital therapeutic
EndeavorRx, which has been cleared by the U.S. Food and Drug Administration (FDA) for use in children with ADHD (see full indication below):
BOSTON(BUSINESS WIRE)Akili Interactive (Akili), a leading cognitive medicine company improving health through game-changing
technologies, today announced that the American Journal of Psychiatry has published findings from the STARS-MDD clinical trial evaluating Akilis
AKL-T03 digital therapeutic as a potential treatment for attention impairments in adults with major depressive disorder (MDD) when used alongside antidepressant medication.
More than 16 million people in the United States are living with MDD.1 Despite the positive
benefits of antidepressant therapy on mood, most pharmacologic treatments provide little or no benefit on cognitive impairments in patients with MDD.234 Many patients with MDD who have
responded to antidepressant treatment continue to report cognitive challenges, including difficulties concentrating, decision making, slowed thinking, and forgetfulness, which have been shown to have an impact on daily activities, like education and
work.5
Society is facing a growing mental health crisis, with depression rates in the U.S.
increasing about 20% during the pandemic. While mood symptoms are most often associated with MDD, equally concerning are the frequent associated cognitive impairments, said Richard Keefe, Ph.D., Professor of Psychiatry at Duke University
Medical Center, and primary investigator of the study. More than ever, we need safe and effective ways to support these patients new tools that can be easily and broadly accessed. Based on the results of this study, AKL-T03 has the potential to play a meaningful role in the treatment of MDD patients.
The STARS-MDD study enrolled 80 adults, ages 25-55, who were stably treated with an antidepressant medication yet were still experiencing mild to moderate symptoms of depression
as well as cognitive impairments. Patients were randomized 1:1 to AKL-T03 or a digital control designed to have an equal expectation of benefit. Results of the study demonstrated that the addition of AKL-T03 to antidepressant therapy significantly improved sustained attention in adults diagnosed with MDD compared to the control (p=0.005), as measured by the Test of Variables of Attention (TOVA), which is a
computerized test cleared by FDA to assess attention deficits and evaluate the effects of interventions in ADHD.